News blog

Proximagen Neuroscience

  • BY: Andrew Hore |
  • POSTED: 14/10/2008 |

Upsher-Smith Laboratories has made its expected $6m investment in Proximagen Neuroscience shares.

The share price paid is around 227p a share, which is more than double the price when the original deal was announced in July and 90% higher than the previous day’s closing price. Upsher-Smith owns 7.1% of Proximagen.

The weakness of sterling has made the deal look even better. The investment was equivalent to £3.03m in July but now it is worth around £3.5m.

The deal relates to PRX1, which is a programme for the symptomatic treatment of Parkinson’s disease based on an improved version of L-Dopa – a known treatment. Proximagen says that the upfront and milestone payments alone could come to $232m (£134m) plus double digit royalties on sales.

This share investment by Upsher-Smith investment was triggered by positive pre-clinical results from PRX1. Upsher-Smith will be responsible for the worldwide development and commercialisation of PRX1 with Proximagen represented on a steering committee.

Proximagen shares rose 7.5p to 127.5p each.

© 2018 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds